Amgen's Imlygic gets EU committee backing; Merck touts Keytruda survival data in NSCLC;

> Amgen ($AMGN) nabbed European backing for a first-in-class cancer treatment, Imlygic, that uses a virus to deliver immunotherapy; the drug is on its way to FDA approval in the U.S. Report

> Merck & Co. ($MRK) touted top-line data showing that its immuno-oncology drug Keytruda helped certain patients with non-small-cell lung cancer live longer. Release

> GlaxoSmithKline ($GSK) won European backing to expand approval of Volibris, a treatment for pulmonary arterial hypertension, to use in combination with other meds. Report

> Novartis' ($NVS) psoriasis med Cosentyx got a thumbs up from Europe's drug approval committee for new uses in ankylosing spondylitis and psoriatic arthritis. Report

> Rare disease specialist Alexion Pharmaceuticals ($ALXN) nabbed an FDA clearance for Strensiq, which treats hypophosphatasia, a genetic disorder. Release | Report

And Finally... A new report linked some types of cancer with consumption of processed meat such as bacon and hot dogs. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

Gilead is working to move CAR-T med Yescarta into other types of NHL, and if data from an interim trial look-in are any indication, it's on its way.